Nebracetam

Nebracetam
Clinical data
ATC code	none;
Legal status
Legal status	AU: S4 (Prescription only); US: Unscheduled Not FDA approved;
Identifiers
	IUPAC name (RS)-4-(Aminomethyl)-1-benzylpyrrolidin-2-one;
CAS Number	97205-34-0 ;
PubChem CID	65926;
ChemSpider	59334 ;
UNII	T30038QI8N;
ChEMBL	ChEMBL2104682 ;
CompTox Dashboard (EPA)	DTXSID00869598 ;
Chemical and physical data
Formula	C12H16N2O
Molar mass	204.273 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C2N(Cc1ccccc1)CC(C2)CN;
	InChI InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2 ; Key:LCAFGJGYCUMTGS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Nebracetam is an investigational drug of the racetam family that is a M₁ acetylcholine receptor agonist in rats.^[1] Based on a human leukemic T cell experiment in 1991, it is believed to act as an agonist for human M1-muscarinic receptors.^[2] It is also believed to act as a nootropic, like many other racetam drugs.^[3] A chemoenzymatic method of synthesis was reported in 2008.^[4] As of 2023^[update], human trials have not yet been conducted.